Fresh analysis suggests that individuals who come off new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a leading health publication shows that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals using such treatments need to be aware of the potential of rapid rebound weight gain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment mass within about a year and a half.
Comparing Approaches
The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.
The team emphasize that people who lose weight through dieting typically have a less rapid weight regain—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Nutrition scientists believe the way of the jabs is key to understanding the amplified regain.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than normal may cause the system to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement results in appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Condition?
The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, given the high risk of weight regain, the treatment should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," similar to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication explain a sudden resurgence of hunger.
"I experienced a trigger that goes on and you become extremely hungry," described a patient.
This challenge is worsened if patients have not developed permanent dietary or behavioural modifications during treatment.
Significant Adoption
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Use is more common among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are effective agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on integrated lifestyle changes.
